jeudi 12 octobre 2017

Onco Actu du 12 octobre 2017

1. Biologie

NIH completes atlas of human DNA differences that influence gene expression [NIH]

3.2 Prévention - Obésité

The second biggest preventable cause of cancer: being overweight [Cancer Research UK]

4. Dépistage, diagnostic et pronostic

Severe shortage of radiologists risks delays to cancer diagnosis, says report [Cancer Research UK]

4.2 Dép., diag. & prono. - Génome

The future of DNA sequencing [Nature]

The rise and fall and rise again of 23andMe [Nature]

4.7 Dép., diag. & prono. - Col de l'utérus

Could Making Cancer Screening Simpler Increase Women's Risk? [NPR]

5. Traitements

Seattle Biotech Blaze Bioscience Adds $16M for Clinical Trial Work [Xconomy]

5.12.2 Immunothérapies - CAR-T

Mustang CAR-T brain tumor trial gets funds to expand [FierceBiotech]

5.2 Pharma

U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia [Astellas]

Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer [janssen]

5.3 Traitements - FDA, EMA, NICE...

Statement by FDA Commissioner Scott Gottlieb, M.D. on new steps by FDA to advance patient engagement in the agency’s regulatory work [FDA]

5.4 Traitements - Economie

New treatment option for people with gastrointestinal cancer [NICE]

NICE backing for Bayer’s Stivarga in GIST [PharmaTimes]

6. Lutte contre les cancers

‘We have entered a new era’: Cancer researchers no longer follow a single path to discovery [STAT]

Last Month in Oncology with Dr. Bishal Gyawali: September 2017 [ecancernews]

Why is so hard do cure Cancer? [TEDEd]

6.10 Politiques

Medicines research warning over Brexit [BBC News]

6.11 Patients

Prostate cancer patients unclear on differences among treatments [Reuters]

6.6 Publications

A journal printed a sharp critique of a paper it had published. If only it had checked with the authors first. [Retraction Watch]